关于 2025 年第二季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京钢铁股份有限公司 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》的 相关规定，南京钢铁股份有限公司（以下简称公司）现将 2025 年第二季度的主 要经营数据公告如下： 一、公司主要财务数据 证券代码：600282 证券简称：南钢股份 公告编号：临 2025-041 单位：元 币种：人民币 主要会计数据 本报告期 （1－6月） 上年同期 本报告期比上年 同期增减（%） 营业收入 28,944,495,409.32 33,678,596,367.88 -14.06 利润总额 1,676,811,782.64 1,427,373,724.70 17.48 归属于上市公司股东的净利润 1,463,086,369.70 1,233,310,671.73 18.63 归属于上市公司股东的扣除非 经常性损益的净利润 1,149,210,487.59 1,016,731,358.05 13.03 经营活动产生的现金流量净额 ...

泡泡玛特上半年收入138.8亿元人民币，同比激增204.4%。毛绒产品收入同比增长1276.2%，一跃成为最大品类，占总收入的44.2%。THE MONSTERS收入48.1亿元，占总收入的34.7%，相比去年同期的13.7%实现了大幅提升。 19日，泡泡玛特公布H1财报： | 中期業績摘要 | | | | | --- | --- | --- | --- | | | 截至6月30日止六個月 | | | | | (未經審核) | (未經審核) | | | | 2025年 | 2024年 | 同比參動 | | | 人民幣千元 | 人民幣千元 | (90) | | 收益 | 13.876.276 | 4.557.831 | 204.4% | | 毛利 | 9,761,064 | 2,919,105 | 234.4% | | 經營溢利 | 6,043,741 | 1,126.417 | 436.5% | | 除所得税前溢利 | 6.156.872 | 1,228.438 | 401.2% | | 期内溢利 | 4,681,713 | 964.142 | 385.6% | | 本公司擁有人應佔溢利 | 4,574,36 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》的 相关规定，南京钢铁股份有限公司（以下简称公司）现将 2025 年第二季度的主 要经营数据公告如下： 一、公司主要财务数据 单位：元 币种：人民币 主要会计数据 本报告期 （1－6月） 上年同期 本报告期比上年 同期增减（%） 营业收入 28,944,495,409.32 33,678,596,367.88 -14.06 利润总额 1,676,811,782.64 1,427,373,724.70 17.48 归属于上市公司股东的净利润 1,463,086,369.70 1,233,310,671.73 18.63 归属于上市公司股东的扣除非 经常性损益的净利润 1,149,210,487.59 1,016,731,358.05 13.03 经营活动产生的现金流量净额 2,265,045,264.79 1,107,375,317.03 ...

又一家A股上市公司筹划赴港IPO。 顺灏股份拟赴港IPO 冲刺A+H 8月14日晚间，上海顺灏新材料科技股份有限公司（以下简称"顺灏股份"）发布公告，公司拟筹划境外发行股份（H股）并在香港联交所主板上市，以积 极响应国家加快发展新质生产力政策号召，促进公司业务转型，深化全球化战略布局。 顺灏股份方面表示，截至目前，公司正积极与相关中介机构就本次发行并上市的相关工作进行商讨，除本次董事会审议通过的相关议案外，其他关于本次 发行并上市的具体细节尚未最终确定。 顺灏股份同时宣布，拟聘请香港立信为本次发行并上市的审计机构。 环保包装新材料领域龙头 上半年增利不增收 资料显示，顺灏股份成立于2004年，总部位于上海，公司产业以环保包装新材料为龙头，以新型烟草制品和工业大麻为两翼，业务板块清晰呈现环保包装 新材料、印刷品、新型烟草及工业大麻四大产业链。公司目前员工近1200人，近30家子公司遍布于海内外，分布在美国、柬埔寨、上海、香港、广东、福 建、湖北、安徽、浙江等地。顺灏股份是《中华人民共和国包装行业标准：真空镀铝纸》的起草单位之一，连续多年被评为上海百强企业。产品除了在国 内销售，还远销北美、南美、欧洲、亚洲、中东 ...

Group 1 - The company is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international competitiveness and financing capabilities [1][1] - The H-share issuance is still in the planning stage and requires approval from the board, shareholders, and regulatory bodies [1][1] - There is significant uncertainty regarding the approval and implementation of the H-share issuance [1][1] Group 2 - The company primarily engages in the production and sale of coal, coke, natural gas, chemical products, and hydrogen fuel cell vehicles, possessing rich coal and coalbed methane resources [2][2] - The company is one of the largest independent producers of commodity coke and coking coal in China, with a complete industrial chain from coal to hydrogen [2][2] - In 2024, the company reported a revenue of 19.031 billion yuan, a year-on-year decrease of 8.55%, and a net loss attributable to shareholders of 1.143 billion yuan compared to a profit of 289 million yuan in the previous year [2][2] Group 3 - The company expects a net loss of between 480 million yuan and 700 million yuan for the first half of 2025, primarily due to a declining market environment affecting coal and coke prices [3][3] - The company aims to closely monitor market changes and optimize its management mechanisms to mitigate adverse impacts and ensure sustainable development [3][3]

Core Viewpoint - Hansoh Pharmaceutical (03692.HK) demonstrated strong performance in its 2025 interim results, showcasing growth driven by innovation and global strategies, with revenue reaching approximately 7.434 billion RMB, a year-on-year increase of about 14.3% [1] Financial Performance - The company reported a profit of approximately 3.135 billion RMB, reflecting a year-on-year growth of about 15.0% [1] - Basic earnings per share were approximately 0.53 RMB, up by about 14.8% year-on-year, with an interim dividend of 0.2316 HKD per share [1] - Operating cash flow for the first half of 2025 was 3.605 billion RMB, with cash and bank deposits totaling 27.104 billion RMB as of June 30, 2025, indicating a solid financial position [1] Revenue Breakdown - Sales revenue from innovative drugs and collaborative products reached approximately 6.145 billion RMB, a year-on-year increase of about 22.1%, accounting for 82.7% of total revenue [1] - Revenue from specific therapeutic areas included approximately 4.531 billion RMB from oncology, 735 million RMB from anti-infection, 768 million RMB from central nervous system, and 1.4 billion RMB from metabolic and other diseases, representing 60.9%, 9.9%, 10.4%, and 18.8% of total revenue respectively [1] R&D Investment - R&D expenditure for the first half of 2025 was approximately 1.441 billion RMB, a year-on-year increase of 20.4%, constituting 19.4% of total revenue [2] - The company is advancing over 70 clinical trials across more than 40 innovative drug projects, with 8 new candidates entering clinical research in the first half of 2025 [2] Key Product Developments - In the first half of 2025, the company initiated 3 new Phase III pivotal registration clinical trials for innovative drugs targeting B7-H3 ADC for bone and soft tissue sarcoma, B7-H4 ADC for ovarian cancer, and an IL23p19 monoclonal antibody for moderate to severe plaque psoriasis [3] - The GLP-1/GIP dual receptor agonist HS-20094 is in Phase III clinical research for obesity or overweight, with over 1,000 subjects dosed [3] Strategic Partnerships - In June 2025, the company granted Regeneron global exclusive rights to the GLP-1/GIP dual receptor agonist HS-20094 (excluding mainland China, Hong Kong, and Macau), receiving an upfront payment of 80 million USD and potential milestone payments up to 1.93 billion USD, along with double-digit royalties on future product sales [4] - The company is actively pursuing global licensing opportunities to accelerate the commercialization of its innovative pipeline, enhancing the commercial value of its products [4]

据介绍，极米科技近年来持续推进全球化发展，行业影响力持续增强。截至目前，公司已累计获得140 项国际大奖，包括红点、iF、Good Design Award、IDEA世界四大工业设计大奖。在品牌出海与全球化 业务布局战略下，公司的产品已进入欧洲、北美、澳大利亚等区域的主要线下渠道，全球覆盖点位达 8000余家。2024年，极米科技的境外营业收入达10.86亿元，同比增长18.94%。据介绍，公司将基于已 有渠道积累，加强产品及品牌出海的精细化运营，持续提升公司品牌和产品在海外消费者心中的认知 度。 截至2024年底，极米科技的全球累计出货量超700万台，稳居全球家用投影市场出货量第一。作为智能 投影行业首家科创板上市企业，公司坚持以技术普惠基因颠覆专业赛道。极米科技董事长钟波表示，公 司正通过持续的技术创新，致力于打破专业级设备的价格壁垒，让卓越的投影性能变得"触手可及"。 极米科技披露的2025年半年度业绩预增公告显示，公司预计2025年上半年实现营业收入16.26亿元，同 比增长1.63%；归母净利润预计为8866.22万元，同比增速达到2062.33%。2025年上半年，极米科技的产 品持续迭代升级，推 ...

Group 1 - The core viewpoint of the news is that Shunhao Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [2] - The company is actively discussing the issuance and listing with relevant intermediaries, and specific details are yet to be finalized [2] - Shunhao Co., Ltd. has appointed Hong Kong Lixin as the auditing firm for this issuance and listing [2] Group 2 - Shunhao Co., Ltd. was established in 2004 and focuses on eco-friendly packaging materials, new tobacco products, and industrial hemp, with a clear business structure [3] - The company employs nearly 1,200 people and has around 30 subsidiaries located in various regions including the US, Cambodia, and several provinces in China [3] - As of August 18, the company's market capitalization is approximately 9.042 billion RMB [3]

Group 1 - The core point of the news is that Guanghong Technology has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets, aiming to raise no more than 1.033 billion yuan for the acquisition of 100% equity in French AC Company and 0.003% equity in TIS factory, as well as to supplement working capital [1][2] - The acquisition of AC Company, which has completed the transfer and become a subsidiary of Guanghong Technology, is significant as AC Company is an important player in the electronic manufacturing services (EMS) sector with strong technical capabilities and customer resources in the automotive electronics industry [1] - Guanghong Technology's internationalization strategy has been ongoing, with previous acquisitions including a controlling stake in an Indian factory and the establishment of new production bases in Vietnam and Bangladesh, marking a new phase in its global layout with the acquisition of AC Company [1] Group 2 - The automotive electronics industry is experiencing significant growth opportunities, driven by the booming new energy vehicle market, with China's new energy vehicle sales reaching 9.495 million units in 2023 and a penetration rate of 31.55%, nearly a 20-fold increase since 2016 [1] - Industry analysts note that there is a complementary relationship between Guanghong Technology and AC Company in product application areas, which is expected to create synergies in customer resources, market channels, and production technology, particularly in the European, American, and African markets [2] - The company emphasizes that the execution of this transaction is not contingent on the approval of the share issuance, as it has already completed the acquisition through self-raised funds, demonstrating management's confidence and strategic determination regarding the acquisition project [2]

Core Viewpoint - LuXiao Technology plans to list on the Hong Kong Stock Exchange to advance its globalization strategy and enhance its international brand image, despite a history of significant losses and lack of shareholder returns since its listing in 2011 [1][12]. Fundraising and Financial Performance - Since its IPO in 2011, LuXiao Technology has raised over 67 billion yuan, but has accumulated a net profit loss of 6.8 billion yuan [5][12]. - From 2016 to 2024, the company raised a total of 61.79 billion yuan through five rounds of private placements, yet reported a cumulative net profit loss of 8 billion yuan during the same period [2][5]. - The company has not paid any cash dividends in the last seven years, with total cash dividends amounting to only 0.37 billion yuan since 2016, which is less than 0.6% of the total fundraising amount [5][6]. Investment Progress and Use of Funds - LuXiao Technology's last fundraising round in July 2022 raised 25.67 billion yuan, but only 2.85 billion yuan has been utilized as of the end of 2024, indicating a mere 11.3% progress on investment projects [7][10]. - The largest project, the third-generation power semiconductor (silicon carbide) industrial park, was allocated 19.4 billion yuan, but only 1.03 billion yuan has been invested, reflecting a progress rate of just 5.29% [7][12]. Revenue Composition and Globalization Claims - Since its listing, LuXiao Technology has maintained a domestic revenue share above 90% for 13 out of 14 years, with the last four years showing over 95% [1][12]. - The company's reported revenues from 2021 to 2024 were 35.53 billion yuan, 33.42 billion yuan, 27.72 billion yuan, and 37.17 billion yuan, with domestic revenues consistently making up over 95% of total revenues [12][13].